|
February 6, 2006 Categories: Uncategorized Posted by admin
he Food and Drug Administration said Friday it would work with Boston Scientific Corp. to quickly resolve corporate-wide regulatory deficiencies.
In a statement, the agency acknowledged it met with top company officials earlier Friday to discuss the serious regulatory problems the FDA outlined in a rare corporate warning letter issued last week.
Full news
|
|
